Patient Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: Findings from a Patient Survey in Europe.

ABSTRACT:

Introduction

Benepali^® was the first etanercept (Enbrel^®) biosimilar to be approved in the European Union. Both Benepali and Enbrel are available as autoinjector devices. In a recent survey, nurses from France, Germany, Italy, Spain, and the United Kingdom (UK) reported that their patients with rheumatoid arthritis (RA) would prefer the Benepali autoinjector compared to the Enbrel MYCLIC autoinjector. To determine whether patients' perceptions were similar to those of the nurses, this survey evaluated patients' perceptions and preferences of the Benepali autoinjector versus the Enbrel MYCLIC autoinjector in the same five European countries.

Methods

Patients with RA using the Enbrel MYCLIC autoinjector participated in a 25-min, face-to-face questionnaire

SUBMITTER: Thakur K 

PROVIDER: S-EPMC5127972 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature